ADAR and cancer: Based on our findings, DNMTi-HDACi could be particularly beneficial in cancer immunotherapy, since it robustly induces the expression of immunogenic TEs and simultaneously downregulates ADAR1, the inhibitor of immunogenic dsRNAs.